Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

Background: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods: In this retrospective cohort study, we analyzed hypoxic COVID–19 patients who were consecutively admitted b...

Full description

Bibliographic Details
Main Authors:	Tariq Kewan, Fahrettin Covut, Mohammed J. Al–Jaghbeer, Lori Rose, K.V. Gopalakrishna, Bassel Akbik
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	EClinicalMedicine
Subjects:	Coronavirus SARS–CoV–2 Interleukin 6 Tocilizumab Cytokine release syndrome
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537020301620

Similar Items

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
by: Danfei Liu, et al.
Published: (2020-10-01)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
by: Pan Li, et al.
Published: (2021-04-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021-04-01)

Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study
by: Melahat Uzel Şener, et al.
Published: (2022-07-01)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study
by: Antonio Mastroianni, et al.
Published: (2020-07-01)

Appropriate use of tocilizumab in COVID-19 infection
by: Şiran Keske, et al.
Published: (2020-10-01)

2020 Updates on tocilizumab indications for clinicians managing patients with severe acute respiratory syndrome coronavirus 2
by: Mohammed A Omair, et al.
Published: (2020-01-01)

Effects of Tocilizumab in COVID-19 patients: a cohort study
by: Christine A. Vu, et al.
Published: (2020-12-01)

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
by: Faryal Farooqi, et al.
Published: (2020-07-01)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
by: Zarębska-Michaluk D, et al.
Published: (2021-07-01)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
by: Tom van Kraaij, et al.
Published: (2020-04-01)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
by: Nicola Potere, et al.
Published: (2020-11-01)

A retrospective analysis of moderate and severe COVID-19 pneumonia with special reference to the use of Adjuvant Tocilizumab
by: Pratik Raval, et al.
Published: (2022-01-01)

Letter to the Editor in response to Chen et al. 2020
by: Jaya Ponnampalam, et al.
Published: (2020-11-01)

Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19
by: Tuqa Alkhateeb, et al.
Published: (2024-05-01)

Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
by: Joanna L Moore, et al.
Published: (2021-01-01)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
by: Yinqiang Zhang, et al.
Published: (2022-06-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)

Tocilizumab In Severe To Critical Confirmed COVID-19: A Case Series At Ulin Referral Hospital Of South Kalimantan
by: Haryati Haryati, et al.
Published: (2021-06-01)

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
by: Pranay Sinha, et al.
Published: (2020-10-01)

Dilemma of Tocilizumab therapy for a patient with critical COVID‐19 disease and neutropenia: Case report and review of the literature
by: Ahmad Al Bishawi, et al.
Published: (2022-05-01)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
by: Sadettin Uslu
Published: (2020-05-01)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
by: Edmund Huang, et al.
Published: (2021-04-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
by: Avi Gurion Kaye, et al.
Published: (2020-11-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2010-05-01)

Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab
by: Jonathan P. Donnelly, et al.
Published: (2021-01-01)

Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
by: Benjamin Rossi, et al.
Published: (2020-10-01)

Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials
by: Tarun Krishna Boppana, et al.
Published: (2022-02-01)

Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India
by: Peta RK, et al.
Published: (2020-12-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01)

Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients
by: Matthew J. Fisher, et al.
Published: (2021-02-01)

Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
by: Alejandro Rodríguez-Molinero, et al.
Published: (2021-06-01)

Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study
by: Jing Zhang, et al.
Published: (2020-10-01)

The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study
by: Mikhail M. Kostik, et al.
Published: (2017-06-01)

Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS)
by: Danielle Leão Cordeiro de Farias, et al.

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
by: A. Cortegiani, et al.
Published: (2021-01-01)